Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT06759220
Starting soon Observational

Hystrolaparoscopic Findings in Infertile Women With Previous Uterine Surgery

NCT06759220 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Observational
Started
2025-09-21
Last updated
2025-01-06

Condition(s) studied

Hystrolaparoscopic Findings in Infertile Women With Previous Uterine Surgeries

Study summary

1. to determine the rate and pattern of abnormal laparoscopic finding among the infertile women with history of previous uterine surgery.
2. To detemine the rate and pattern of abnormal hysteroscopic finding among infertile women with with history of previous uterine sergery
3. to evaluate the value of doing combined laparoscopy and hysteroscopy in infertile women with with history of previous uterine surgery.
4. To determine possible risk factors of pelvic adhesions detected during laparoscopy.
5. To determine possible risk factors causing cs niche.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
35 Years
Healthy volunteers
No
Inclusion Criteria: * All women between20 to 35 yrs old with secondary infertiliy for 2 years * Women with previous uterine surgery Exclusion Criteria: * Female with major medical illness(Uncontrolled daibetes, cardiac diseases, uncontrolled thyroid disorders) * Abnormal semen parameter of the husband.

Primary outcome measure(s)

  • Primary (main): rate and pattern of abnormal laparoscopic and hysteroscopic findings in infertile women with previous uterine surgery — Baseline
    Primary (main): rate and pattern of abnormal laparoscopic and hysteroscopic findings in infertile women with previous uterine surgery

Trial sites (1)

FacilityCityRegionStatus
Women's health hospital Assiut University Asyut Egypt

More Assiut University trials in Egypt

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder Recruiting
The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion Starting soon
Maternal Iron Deficiency and/or Iron Deficiency Anemia to Neonatal Hemoglobin Concentration and Iron Stores Starting soon
Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon
Intraoperative Lidocaine Infusion Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06759220 on ClinicalTrials.gov ↗ ← All trials in Egypt